ImmunityBio Reports Record Q1 Revenue and Strong Cash Position, Driven by ANKTIVA Growth
IBRX has more than doubled off its 52-week low of $1.83.
Summary
ImmunityBio announced strong preliminary Q1 2026 financial results, including record net product revenue of $44.2 million and a healthy cash balance of $380.9 million, driven by ANKTIVA's continued commercial success.
Key Events · Earnings and Guidance · IBRX
-
Record Q1 2026 Net Product Revenue
Reported preliminary net product revenue of $44.2 million for Q1 2026, representing a 168% increase year-over-year compared to Q1 2025 and a 15% sequential increase from Q4 2025.
-
Strong Cash Position
Ended Q1 2026 with an estimated $380.9 million in cash, cash equivalents, and marketable securities.
-
ANKTIVA Commercial Momentum
ANKTIVA unit sales volume increased by 168% year-over-year in Q1 2026, with the product now approved or authorized in 5 regulatory jurisdictions, encompassing approximately 34 countries.
-
Positive Clinical & Regulatory Updates
NCCN Clinical Practice Guidelines were updated in March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC with papillary-only disease. Additionally, the pivotal BCG-naïve NMIBC CIS trial (QUILT-2.005) is fully enrolled, with a supplemental BLA submission on track for 2026.
Analysis · IBRX · Life Sciences
ImmunityBio's preliminary Q1 2026 results demonstrate robust commercial execution for ANKTIVA, with significant year-over-year and sequential revenue growth. The substantial cash balance provides financial flexibility, while positive clinical and regulatory updates further strengthen the company's long-term outlook. This official filing confirms the strong preliminary results previously reported by news outlets today. Investors should monitor the final Q1 2026 10-Q for confirmation of these preliminary figures and continued ANKTIVA adoption.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IBRX was trading at $6.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2B. The 52-week trading range was $1.83 to $12.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.